Katharine K Duncan

This inventor holds 11 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 4 EPO patents. Top assignees: Abide Therapeutics, Inc., H. Lundbeck A/s, Lundbeck La Jolla Research Center, Inc.. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Katharine K Duncan. Retrieved from https://idiyas.com/inventor/katharine-k-duncan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 1)

% Patents Active = 90.9

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 5.2

ph-index = 3

Forward Citations = 31(Granted Patents)

Company Filing History:

4 out of 18

Abide Therapeutics, Inc.

Lundbeck La Jolla Research Center, Inc.

The Mclean Hospital Corporation

patents

where one patent can have more than one assignee

Years Active: 2013-2025

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12318383 - Dual MAGL and FAAH inhibitors (2025-06-03),

2. 12258340 - Pyrazole MAGL inhibitors (2025-03-25),

3. 11655217 - Pyrazole MAGL inhibitors (2023-05-23),

4. 11149037 - Pyrazole MAGL inhibitors (2021-10-19),

5. 11129827 - Dual MAGL and FAAH inhibitors (2021-09-28),

6. 10927105 - Pyrazole MAGL inhibitors (2021-02-23),

7. 10385057 - Pyrazole compounds and methods of making and using same (2019-08-20),

8. 10350205 - Dual MAGL and FAAH inhibitors (2019-07-16),

9. 10323038 - Pyrazole compounds and methods of making and using same (2019-06-18),

10. 10266497 - Pyrazole MAGL inhibitors (2019-04-23),

11. 8492564 - Salvinorin derivatives and uses thereof (2013-07-23),

Title: Inventor Spotlight: Katharine K Duncan

Introduction

Katharine K Duncan is a prominent inventor based in San Diego, California, known for her groundbreaking work in the field of medicinal chemistry. With a remarkable portfolio comprising nine patents, she has made significant contributions to the development of therapeutics, particularly in pain treatment.

Latest Patents

Among her latest innovations are pyrazole MAGL inhibitors. These pyrazole compounds and their pharmaceutical compositions have been designed to modulate monoacylglycerol lipase (MAGL). The therapeutic potential of these compounds lies in their usefulness for treating pain, showcasing Katharine's dedication to enhancing medical treatment options.

Career Highlights

Katharine has established her career through key roles in reputed organizations, notably Abide Therapeutics, Inc. and Lundbeck La Jolla Research Center, Inc. Her work has not only resulted in valuable intellectual property but has also advanced the understanding of pain modulation at the biochemical level.

Collaborations

Throughout her professional journey, Katharine has collaborated with notable colleagues, including Cheryl A Grice and Olivia Delene Weber. These partnerships emphasize the collaborative nature of innovation, which is vital in the field of research and development.

Conclusion

Katharine K Duncan exemplifies the impact an inventor can have on healthcare through innovation. With her extensive work on pyrazole MAGL inhibitors and her collaborations with industry leaders, she continues to pave the way for future advancements in pain management and pharmaceutical development. Her achievements underscore the importance of creativity and scientific inquiry in addressing complex medical challenges.

Profile summary based on public USPTO records.